RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

>>> RespireRx Pharmaceuticals Inc. to Present at the Jefferies 2016 Healthcare Conference



http://finance.yahoo.com/news/respirerx-pharmaceuticals-inc-present-jefferies-120000636.html




GLEN ROCK, NJ--(Marketwired - Jun 8, 2016) - RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company's President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Jefferies 2016 Healthcare Conference (www.jefferies.com) in New York, New York on Friday, June 10, 2016 at 10:00 AM Eastern Time. The Conference is sponsored by Jefferies & Company, Inc. and is being held at The Grand Hyatt Hotel, New York, New York, from June 7 through June 10, 2016.

Commented Dr. Manuso, "The presentation at the Jefferies Conference will update investors on RespireRx's strategic initiatives and progress on research and development programs. I look forward to discussing the Company's ongoing Phase 2A clinical trial evaluating the impact of the proprietary oral ampakine, CX-1739, on opioid-induced respiratory depression." Dr. Manuso will also provide information on the Company's other product pipeline candidates, including dronabinol, and the Company's development timelines. Dr. Manuso concluded, "We look forward to further updating shareholders and other stakeholders on the progress of RespireRx's scientific, clinical and regulatory development initiatives during 2016."

Dr. Manuso's presentation and accompanying slides will be accessible live, via webcast, at http://wsw.com/webcast/jeff97/rspi/lobby=tru. Replays will be available one hour after the presentation at the same link. A copy of the slide deck to be presented at the conference will be available on RespireRx's website at www.respirerx.com, by clicking on the investors tab and following the links. A copy of the slide presentation to be presented at the conference will be submitted in a filing by the Company with the U.S. Securities and Exchange Commission in a Current Report on Form 8-K prior to the presentation and will also be available in the investors section of the RespireRx website.

About RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, with a focus on sleep apneas and drug-induced respiratory depression. The Company holds exclusive licenses and owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.

RespireRx's pharmaceutical candidates in development are derived from two platforms, as described below.

One platform of medicines being developed by RespireRx is a class of proprietary compounds known as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors. Several ampakines, in both oral and injectable form, are being developed by the Company for the treatment of a variety of breathing disorders. In clinical studies, select ampakines have shown preliminary efficacy in central sleep apnea and in the control of respiratory depression produced by opioids, without altering the opioid analgesic effects. In animal models of orphan disorders, such as Pompe Disease, spinal cord damage and perinatal respiratory distress, it has been demonstrated that certain ampakines improve breathing function. The Company's compounds belong to a new class that does not display the undesirable side effects previously reported for other ampakines.

The other platform is the class of compounds known as cannabinoids, including, in particular, dronabinol. Under a license agreement with the University of Illinois, the Company has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol produced a statistically significant reduction in the Apnea-Hypopnea Index, the primary therapeutic end-point, and was observed to be safe and well-tolerated in a group of patients with Obstructive Sleep Apnea ("OSA"). The University of Illinois and three other centers have completed the dosing of a potentially pivotal, six week, double-blind, placebo-controlled Phase 2B clinical trial investigating the effects of dronabinol in 120 patients with OSA. The Company is not managing or funding this clinical trial, which is fully funded by the National Heart, Lung and Blood Institute of the National Institutes of Health.

<<<